Get the latest news on NetEase stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on NETTF performance

Latest NetEase Stock News | OTC:NETTF | Benzinga

Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.

NetEase Inc

<p>Cryptocurrency markets are rebounding from an overnight dip that saw Bitcoin go <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44039431/bitcoin-plummets-below-80000-ethereum-xrp-dogecoin-get-hammered-as-crypto-crash-continues">as low as $78,300</a>.</p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Bitcoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$84,650.16</td>
<td>+1.7%</td>
</tr>
<tr>
<td><strong>Ethereum</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$2,233.35</td>
<td>-1.7%</td>
</tr>
<tr>
<td><strong>Solana</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>&nbsp;$146.31</td>
<td>+8.3%</td>
</tr>
<tr>
<td><strong>XRP </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.15</td>
<td>-0.7%</td>
</tr>
<tr>
<td><strong>Dogecoin</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.2013</td>
<td>-0.9%</td>
</tr>
<tr>
<td><strong>Shiba Inu</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00001389</td>
<td>-2.8%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Notable Statistics:</strong></p>
<ul>
<li>IntoTheBlock data shows large transaction volume decreasing by 26.1%. Daily active addresses grew by 6.3%. Transactions greater than $100,000 are down from 13,305 to 12,754 in a single day. Exchanges netflows are down by 148.7%.</li>
<li>Coinglass data reports 233,253 traders were liquidated in the past 24 hours for $1.01 billion.</li>
<li>IntoTheBlock data shows Bitcoin's active addresses reached the highest daily level since December 2024. Spikes in on-chain activity coincides with market peaks and bottoms. This surge implies the market could be at a crucial turning point.</li>
</ul>
<p><strong>Notable Developments:</strong></p>
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44048486/bitcoins-24-correction-mostly-technical-say-experts">Bitcoin&#8217;s 24% Correction &#8216;Mostly Technical&#8217; Say Experts</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44050992/the-real-reason-why-bitcoin-is-down-14-in-7-days-and-may-go-down-more">The Real Reason Why Bitcoin Is Down 14% In 7 Days (And May Go Down More)</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44041389/bitcoin-will-still-hit-500000-before-trump-leaves-office-standard-chartered-analyst-maintains">Bitcoin Will Still Hit $500,000 Before Trump Leaves Office, Standard Chartered Analyst Maintains</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44046215/bitvm-integration-unlocks-bitcoins-19-trillion-liquidity-across-five-major-blockchains">BitVM Integration Unlocks Bitcoin&#8217;s $1.9 Trillion Liquidity Across Five Major Blockchains</a></li>
<li><a href="https://www.benzinga.com/25/02/44032261/michael-saylor-advocates-for-us-leadership-in-bitcoin-and-crypto-to-house-financial-services-committee">Michael Saylor Presents &#8216;Digital Assets Framework&#8217; To House Committe, Pitches For US Supremacy In Bitcoin, Crypto</a></li>
</ul>
<p><strong>Top Gainers:</strong></p>
<p><figure class="wp-block-table"><br />
<table>
<tbody>
<tr>
<td><strong>Cryptocurrency</strong></td>
<td><strong>Price&nbsp;&nbsp;&nbsp;</strong></td>
<td><strong>Gains +/-</strong></td>
</tr>
<tr>
<td><strong>Berachain</strong> (CRYPTO: BERA)</td>
<td>&nbsp;$8.41</td>
<td>+12.4%</td>
</tr>
<tr>
<td><strong>Celsetia</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">TIA</a>)</td>
<td>&nbsp;$4.05</td>
<td>+12.3%</td>
</tr>
<tr>
<td><strong>Hedera</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/hbar/usd">HBAR</a>)</td>
<td>&nbsp;$0.2151</td>
<td>+10%</td>
</tr>
</tbody>
</table>
<p></p></figure></p>
<p><strong>Trader Notes: </strong>BTC has fallen 19% over the past week, prompting trader Altcoin Sherpa to question whether a short-term recovery is possible.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">Lets see if we can break this cycle of poverty in the short term for <a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> <a href="https://t.co/ZWhyzAsXXz">pic.twitter.com/ZWhyzAsXXz</a></p>
<p>&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1895533795186774154?ref_src=twsrc%5Etfw">February 28, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Santiment data highlights how traders consistently misjudge BTC's direction. Mentions of $70,000-$75,000 (bearish) and $90,000-$95,000 (bullish) indicate that when traders expect BTC to rise, it falls—and vice versa.</p>
<p>Trader Blockchainedbb points to liquidity above $107,000, with $110,000 as the next major profit-taking zone. Meanwhile, CrediBULL Crypto sees relief after BTC tagged $79,000, expecting a base to form between $74,000 (HTF demand) and $94,000-$99,000 (local supply) before a full reversal.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">More like 2025! Liquidity above 107k ! Around 110k ish is next major profit taking <a href="https://t.co/LDM2mEVSMH">https://t.co/LDM2mEVSMH</a> <a href="https://t.co/GQeVR1xgOF">pic.twitter.com/GQeVR1xgOF</a></p>
<p>&mdash; Blockchainedbb (@blockchainedbb) <a href="https://twitter.com/blockchainedbb/status/1895558550178734140?ref_src=twsrc%5Etfw">February 28, 2025</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p><strong>Read Next:&nbsp;</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44044388/michael-saylor-says-sell-a-kidney-but-keep-the-bitcoin-but-mstr-is-down-28-since-he-appeared-on-the-cover-of-forbes">Michael Saylor Says &#8216;Sell A Kidney, But Keep The Bitcoin&#8217;, But MSTR Is Down 28% Since He Appeared On The Cover Of Forbes</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

$DOGE

$ETH

$HBAR

$SHIB

$SOL

$TIA

$XRP

Bitcoin, Ethereum, XRP, Dogecoin Rebound From The Brink: Here Are The Key Levels To Watch

<p>Ukraine&#8217;s President <strong>Volodymyr Zelenskyy</strong> met with President <strong>Donald Trump</strong> and Vice President <strong>JD Vance</strong> on Friday but left the White House without signing an <a href="https://www.benzinga.com/news/global/25/02/44053592/white-house-meeting-turns-tense-as-trump-warns-zelenskyy-youre-gambling-with-world-war-iii">agreement for rare minerals</a>.</p>
<p>The meeting, originally set to finalize the deal over critical minerals as a form of repayment for military aid, escalated into a heated exchange as Trump accused the Ukrainian leader of<a href="https://www.benzinga.com/news/global/25/02/44053592/white-house-meeting-turns-tense-as-trump-warns-zelenskyy-youre-gambling-with-world-war-iii"> "gambling with World War III."</a></p>
<p>"You're either going to make a deal or we're out," Trump noted. "And if we're out, you'll fight it out and I don't think it's going to be pretty."</p>
<p>Trump&#8217;s administration moved to sign the proposal earlier this month, but <a href="https://www.benzinga.com/markets/commodities/25/02/43788546/ukraine-officials-stall-trumps-colonial-rare-earths-bid-prefer-mutually-beneficial-deal">Ukrainian officials stalled</a>. They called the bid exploitative and rushed and stated that Kyiv could not accept it in that form.</p>
<p>After weeks of negotiation, the two parties found common ground, dropping Trump&#8217;s original $500 billion proposal but <a href="https://www.benzinga.com/25/02/43968607/trump-negotiates-a-very-big-deal-for-ukraines-mineral-wealth">not including security guarantees</a> — one of Kyiv&#8217;s key demands, which Trump wanted to address "later on." According to the Kiel Institute for the World Economy, the U.S. donated $118 billion during the three-year conflict.</p>
<p>Rare earth minerals are used in numerous modern technologies, from electric vehicles to defense systems. Per EU classifications, Ukraine holds deposits of 22 out of 34 of those minerals. Still, in a war-ridden country, getting to those minerals might be an issue.</p>
<p>According <a href="https://www.aljazeera.com/news/2025/2/28/mapping-ukraines-rare-earth-and-critical-minerals">to</a> Al Jazeera, most of those deposits are in Luhansk, Donetsk, Zaporzhizhia, Dnipropetrovsk, Korovohrad, Poltava and Kharkiv, with the Russian Federation controlling about 40% of them.</p>
<p>Besides the war factor, BCA Research Chief Strategist <strong>Marko Papic</strong> noted yet another issue.</p>
<p>"Even if you somehow manage to get the rare earths out, the question would be — where do you refine them? And the fact is that most of them would have to go to China. I mean, that&#8217;s the critical bottleneck in this whole situation," he <a href="https://www.linkedin.com/posts/marko-papic-geopolitics_does-the-rare-earth-deal-matter-im-out-activity-7301045940683997184-YB4b?">said</a> on LinkedIn.</p>
<p>Furthermore, Papic sees the entire situation as Trump&#8217;s way of garnering domestic support.</p>
<p>"I think it&#8217;s the way to effectively build domestic political consensus for continued support of Ukraine. Many of his voters, many of his supporters, many conservatives in the U.S., specifically Republican voters, are increasingly becoming skeptical of continued support for Ukraine. Polling shows that the vast majority believe that Ukraine&#8217;s aid has already been too much. Therefore, this is the way for President Trump to do something domestically," he noted, pointing at the parallels with the USMCA agreement from 2020.</p>
<p>"This is something that President Trump does over and over again. The theater surrounding many of his deals, the back and forth, calling countries bad names, saying they should be states of the United States &#8230; that&#8217;s in many ways designed to build domestic consensus, particularly among his voters," Papic concluded</p>
<p><strong>Read Next:</strong> <br />     • <a href="https://www.benzinga.com/media/25/02/44052145/taiwan-semi-faces-geopolitical-strain-due-to-us-scrutiny-on-huaweis-chip-access">Taiwan Semi Faces Geopolitical Strain Due To US Scrutiny On Huawei&#8217;s Chip Access</a></p>


Commodities

Politics

Global

Markets

'This Is Something That President Trump Does Over And Over Again,' Geopolitical Strategist Says About Failed Rare Minerals Deal With Ukraine President Zelenskyy

<p>Stablecoins are the future of commerce, according to <strong>Tom Vieira</strong>, Head of Product for <strong>Base</strong>, <strong>Coinbase</strong>'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) <strong>Ethereum </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) Layer-2 network. He highlighted on Friday their role in driving a global <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43810566/stablecoins-are-a-big-deal-but-not-where-youd-expect-bernstein-says">on-chain economy</a>.</p>
<p><strong>What Happened: </strong>Speaking with Benzinga in an interview, Vieira pointed to stablecoins' utility in payments as a key example of real-world cryptocurrency adoption, alongside gaming and social applications, as Base scales to meet consumer needs with recent performance boosts.</p>
<p>Vieira elaborated on stablecoins' practicality within Base's ecosystem, emphasizing their potential to enable local currency transactions worldwide. </p>
<p>"Stablecoins really are the future of commerce and we are passionate," he said, detailing a vision where every country could have its own stablecoin, preserving local economic preferences over dollarization.</p>
<p>He cited Base's "Based Around the World" tour last year—spanning Kenya, India, Thailand, Singapore, Malaysia, and the Philippines—as evidence of this push, bolstered by a testnet upgrade cutting transaction times to 200 milliseconds from two seconds, with mainnet rollout pending.</p>
<p>Beyond payments, Vieira highlighted gaming and social platforms as additional on-chain successes. In gaming, apps like Blocklord's Dynasty and Super Champs allow players to own and earn from digital collectibles, unlike Web2 models such as Fortnite. </p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44048486/bitcoins-24-correction-mostly-technical-say-experts">Bitcoin&#8217;s 24% Correction &#8216;Mostly Technical&#8217; Say Experts</a></strong></p>
<p>Socially, "Apps like Farcaster, Zora, and Rodeo are really innovating to help connect fans closer with creators so that creators earn more," he said, noting higher creator take rates compared to traditional media. </p>
<p>These use cases, he argued, demonstrate adoption beyond speculation, supported by Base's focus on builder sustainability through grants and build-a-thons, including last year's $1 million ETH giveaway.</p>
<p>Vieira tied Base's efforts to broader Ethereum scaling, with contributions like blob space enhancements, while addressing decentralization. </p>
<p>"We want to make sure that we strike the right balance of a performance sequencer that is fast, affordable block space, but that still maintains the good critical properties of blockchain," he said, referencing fault proofs launched last quarter and a 2025 stage-one decentralization goal. </p>
<p>Base's smart wallet, now with sub-accounts, aims to ease onboarding, a bottleneck he sees as critical to mainstream adoption.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/44046215/bitvm-integration-unlocks-bitcoins-19-trillion-liquidity-across-five-major-blockchains">BitVM Integration Unlocks Bitcoin&#8217;s $1.9 Trillion Liquidity Across Five Major Blockchains</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


COIN

Stablecoins Are Future Of Commerce, Says Base's Tom Vieira

<p>Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>) has outperformed the market over the past 15 years by 1.88% on an annualized basis producing an average annual return of 13.42%. Currently, Valero Energy has a market capitalization of $40.86 billion. </p>
<p><strong>Buying $1000 In VLO:</strong> If an investor had bought $1000 of VLO stock 15 years ago, it would be worth <strong>$6,628.26</strong> today based on a price of $129.72 for VLO at the time of writing.</p>
<h3>Valero Energy's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740773751_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Trading Ideas

$1000 Invested In Valero Energy 15 Years Ago Would Be Worth This Much Today

<p>In the current market session, <strong>Fidelity National Info Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>)</strong> share price is at $70.51, after a <strong>1.82%</strong> increase. Moreover, over the past month, the stock decreased by <strong>13.45%</strong>, but in the past year, went up by <strong>1.53%</strong>. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1740773733_0.png" alt="Past Year Chart" /></p>

<h3>Comparing Fidelity National Info P/E Against Its Peers</h3>
<p>The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. </p>
<p>Fidelity National Info has a lower P/E than the aggregate P/E of <strong>91.93</strong> of the Financial Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1740773733_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

A Look Into Fidelity National Info Inc's Price Over Earnings

<p>Over the last 6 sessions, many formerly high-flying stocks are down, massively. PLTR has lost over 31% during this period. SCMI shed almost the same. TSLA is down over 22%.</p>
<p>While many of these tickers may have good long-term reasons to be bullish, knowing when to take profits, when to protect the downside, and when to flip bearish is crucial.</p>
<p>There is no technical indicator or chart that is going to give you that information. Option dealers and market makers don't care about your support and resistance levels. They have to delta hedge regardless of whether your levels are breached.&nbsp; And any horizontal levels you pick on your chart will rarely ever depict where and when volatility will increase and the chances for your ticker to go bearish jump.</p>
<p>What if you could know for any ticker you trade when it becomes more vulnerable? What if you could know at what price the option dealers and market makers are going to sell as it falls, not buy? How about knowing when volatility could expand and thus kick your stop losses or take on bigger moves?</p>
<p><strong><u>There is a way to find this exact price.</u></strong></p>
<p>Here at Benzinga, and particularly in the Benzinga Option School, we've built a proprietary indicator that does just this. We call it the BBP level, otherwise known as the Bull/Bear Pivot level.</p>
<p>While I'm not going to give away the keys to the kingdom, I can tell you this proprietary indicator is based upon two key principles (and a lot of quantitative data). First, it's based upon option positioning (all of it for each ticker). Second, it estimates exactly where the option dealer and market maker hedging shifts to where the dealers will have to sell if the market goes down, not buy.</p>
<p>If you buy a dip and the dealers are buying, the chances of your bullish trade working out increase dramatically. But if you buy a dip and the dealers are forced to sell, they are trading against you, and you're fighting against a much larger force that will severely impact your trade.</p>
<p>This is exactly what the BBP level provides our <strong>Benzinga Option School</strong> members, and it can give you a massive edge on knowing when to buy that dip, or to sell. When to hedge or keep your bullish exposure. When to reduce leverage or buy downside protection.</p>
<p>Let me give a few examples below of the BBP level in action:</p>
<h2 class="wp-block-heading">TSLA &amp; the BBP Level</h2>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="612" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-1024x612.png" alt="" class="wp-image-804428" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-1024x612.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma-768x459.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145128/tsla-gamma.png 1289w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p>The chart above shows many of our proprietary quantitative levels for Tesla option positioning, particularly examining a primary variable for the open interest.</p>
<p>You'll see pink bars on the left (puts) and blue bars on the right (calls).</p>
<p>On the top left, you'll see an orange flag which says "Pivot" on it. That is our BBP level, our Bull/Bear Pivot. Here, that ‘pivot' is lined up at $400.</p>
<p>The basic rules of thumb when using and trading with this is as follows:</p>
<ol>
<li>When the stock trades below the BBP level, we take profits on our bullish positions + do not add any new bullish positions</li>
<li>If we get deeper into the pink territory (all depends upon the structure of the pink bars), we then consider hedging any long stock positions we want to keep.</li>
<li>If certain ‘changes' happen in our structure or levels, then we'll look for outright bearish positions.</li>
</ol>
<p>If you look at the following chart below for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), you can see that once we had our impulsive break and close below $400, it's been (for the most part) a one-way train, losing over 29% since and only weak/corrective bounces.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1024x502.png" alt="" class="wp-image-804430" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145156/TSLA_2025-02-27_14-26-26.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p class="has-text-align-center"><em>TSLA 1hr chart</em></p>
<p>Now I'd like you to think about what it would be like to have a level, that if you break below, you either a) trim your bullish positions, b) maybe sell some calls to lower your cost basis, c) start to hedge and protect your downside, or d) shift to outright bearish mode and make money as the stock goes down?</p>
<p>What would that do for your trading to have these levels every day?</p>
<p>How much money would it save you holding onto losing positions?</p>
<p>What would it do for your confidence to ‘know' when to start shifting from bullish to bearish with clarity?</p>
<p>By the way, let me let you in on a few other BBP levels:</p>
<ul>
<li>On February 19, our BBP level for Palantir (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) was $115, and it closed at $112 on that day. Since then, it's lost 24%.</li>
<li>On February 25, Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) had its BBP level at $53. The next day, it fell below our BBP level and has dropped 15% since.</li>
<li>NVDA had its BBP level at $130, as I'm writing this, which I  warned our Benzinga Option School members about ahead of time, saying:</li>
</ul>
<p>"<em>If NVDA can recapture 140, this means calls are completely in control, so should find more supportive flows above there. Meanwhile <strong>losing 130 would bring puts more into control</strong>, and thus <u>a more vulnerable position for NVDA</u>."</em></p>
<p>I told our members <em>before</em> the market opened that if NVDA fell below the 130 level (the BBP level), it would be vulnerable to losses as dealers would start selling as it fell.</p>
<p>NVDA closed today at $10 lower and $120.31.&nbsp;</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1024x502.png" alt="" class="wp-image-804431" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1024x502.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-768x377.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59-1536x753.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/28145217/NVDA_2025-02-27_14-41-59.png 1835w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p class="has-text-align-center"><em>NVDA 5min chart</em></p>
<p>Our members were prepared <strong><em>ahead</em> of time</strong> to reduce bullish positions and start looking for bearish plays.</p>
<p>Had you known about this today, you likely would have saved yourself a ton of money. Now imagine that but having the knowledge and level every day you trade. What would that do for your trading? How many big losses would be smaller? How many times would you be able to profit from a shift in bearish positioning?</p>
<p>That is the power of the BBP level.</p>
<p>If you'd like to learn more about the BBP level, or see me use trading live, you can become a member of the <strong><a href="https://www.benzinga.com/premium/ideas/benzinga-options-school-webinar/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0301&amp;utm_campaign=optionsschool">Benzinga Option School.</a></strong></p>
<p>I look forward to working with you and teaching you how to use this BBP level for your trading.</p>
<p>Image via MidJourney AI</p>


Opinion

PLTR

SMCI

TSLA

How I Saw This Tech Crash Coming a Mile Away – And You Could Have Too

WIIM

CARS

Cars.Com shares are trading higher, reversing after falling Thursday on worse-than-expected Q4 financial results.

<p>In the latest quarter, 11 analysts provided ratings for Aflac (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AFL#NYSE">AFL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Aflac, revealing an average target of $103.64, a high estimate of $118.00, and a low estimate of $94.00. Surpassing the previous average price target of $103.00, the current average has increased by 0.62%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772856_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Aflac. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$105.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$104.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$95.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$118.00</td>
<td>$122.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$104.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$107.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$98.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$102.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Aflac. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Aflac compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Aflac's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Aflac's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AFL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Aflac analyst ratings.</strong></a></p>
<h2>Discovering Aflac: A Closer Look</h2>
<p>Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.</p>
<h3>Aflac: A Financial Overview</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Revenue Growth:</strong> Aflac's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>44.53%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Aflac's net margin excels beyond industry benchmarks, reaching <strong>34.59%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>7.47%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.55%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Aflac's debt-to-equity ratio is below the industry average at <strong>0.29</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

11 Analysts Have This To Say About Aflac

<p>In the latest quarter, 8 analysts provided ratings for Lincoln National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $37.88, a high estimate of $44.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 6.7% increase from the previous average price target of $35.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772849_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Lincoln National among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Thomas Gallagher</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$44.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$39.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$38.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Lincoln National. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lincoln National compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Lincoln National's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>To gain a panoramic view of Lincoln National's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/LNC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Lincoln National analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Lincoln National</h2>
<p>Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.</p>
<h3>Understanding the Numbers: Lincoln National's Finances</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Lincoln National's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>605.13%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Lincoln National's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>32.91%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Lincoln National's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>21.86%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Lincoln National's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.42%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Lincoln National's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>0.87</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Lincoln National Through 8 Analysts

<p>Deep-pocketed investors have adopted a bullish approach towards Intuitive Machines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LUNR usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 18 extraordinary options activities for Intuitive Machines. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 44% leaning bullish and 38% bearish. Among these notable options, 5 are puts, totaling $330,540, and 13 are calls, amounting to $4,304,059.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.5 to $19.0 for Intuitive Machines over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Intuitive Machines's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Intuitive Machines's substantial trades, within a strike price spectrum from $10.5 to $19.0 over the preceding 30 days.</p>
<h3>Intuitive Machines 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772847_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.55</td>
<td>$12.00</td>
<td>$1.8M</td>
<td>2.0K</td>
<td>7.9K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.5</td>
<td>$3.45</td>
<td>$3.45</td>
<td>$12.00</td>
<td>$764.3K</td>
<td>2.0K</td>
<td>13.5K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$12.00</td>
<td>$679.5K</td>
<td>2.0K</td>
<td>15.6K</td>
</tr>
<tr>
<td>LUNR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.45</td>
<td>$3.0</td>
<td>$3.35</td>
<td>$12.00</td>
<td>$477.8K</td>
<td>2.0K</td>
<td>61</td>
</tr>
<tr>
<td>LUNR</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/28/25</td>
<td>$5.1</td>
<td>$4.9</td>
<td>$5.0</td>
<td>$19.00</td>
<td>$100.0K</td>
<td>1.1K</td>
<td>205</td>
</tr>
</tbody>
</table>
</p>
<h3>About Intuitive Machines</h3>
<p>Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure.</p>
<h3>Current Position of Intuitive Machines</h3>
<ul>
<li>Trading volume stands at 13,228,001, with LUNR's price up by 2.4%, positioned at $14.74.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What The Experts Say On Intuitive Machines</h3>
<p>Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $16.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $16. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Intuitive Machines options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

LUNR

Decoding Intuitive Machines's Options Activity: What's the Big Picture?

<p>Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) has outperformed the market over the past 5 years by 17.19% on an annualized basis producing an average annual return of 31.55%. Currently, Fluor has a market capitalization of $6.43 billion. </p>
<p><strong>Buying $1000 In FLR:</strong> If an investor had bought $1000 of FLR stock 5 years ago, it would be worth <strong>$3,794.82</strong> today based on a price of $38.10 for FLR at the time of writing.</p>
<h3>Fluor's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772846_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much $1000 Invested In Fluor 5 Years Ago Would Be Worth Today

<p>Ratings for Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $16.38, a high estimate of $32.00, and a low estimate of $6.00. Highlighting a 10.88% decrease, the current average has fallen from the previous average price target of $18.38. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772842_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Iovance Biotherapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Ulz</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$6.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$32.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Iovance Biotherapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Iovance Biotherapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Iovance Biotherapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Iovance Biotherapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/IOVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Iovance Biotherapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Iovance Biotherapeutics's Background</h2>
<p>Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.</p>
<h3>Financial Insights: Iovance Biotherapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Iovance Biotherapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>12384.86%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-142.67%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Iovance Biotherapeutics's ROE excels beyond industry benchmarks, reaching <strong>-10.84%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Iovance Biotherapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-8.54%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Iovance Biotherapeutics's debt-to-equity ratio is below the industry average at <strong>0.1</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


IOVA

Forecasting The Future: 4 Analyst Projections For Iovance Biotherapeutics

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Axon Enterprise</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with AXON, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 27 uncommon options trades for Axon Enterprise.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 29% bullish and 51%, bearish.</p>
<p>Out of all of the special options we uncovered, 11 are puts, for a total amount of $805,664, and 16 are calls, for a total amount of $1,363,222.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $195.0 to $720.0 for Axon Enterprise during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale activity within a strike price range from $195.0 to $720.0 in the last 30 days. </p>
<h3>Axon Enterprise Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772841_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$62.4</td>
<td>$58.5</td>
<td>$61.3</td>
<td>$470.00</td>
<td>$619.1K</td>
<td align="right">175</td>
<td align="right">0</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$126.3</td>
<td>$122.8</td>
<td>$125.0</td>
<td>$650.00</td>
<td>$275.0K</td>
<td align="right">169</td>
<td align="right">23</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$41.4</td>
<td>$40.0</td>
<td>$40.0</td>
<td>$500.00</td>
<td>$200.0K</td>
<td align="right">100</td>
<td align="right">52</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$19.9</td>
<td>$18.0</td>
<td>$18.0</td>
<td>$650.00</td>
<td>$162.0K</td>
<td align="right">433</td>
<td align="right">90</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$187.0</td>
<td>$184.5</td>
<td>$184.5</td>
<td>$400.00</td>
<td>$92.2K</td>
<td align="right">4</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Axon Enterprise</h3>
<p>Axon Enterprise Inc develops, manufactures, and sells conducted energy devices and cloud-based digital evidence management software designed for use by law enforcement, corrections, military forces, private security personnel, and private individuals for personal defense. The company operates in two segments: Taser and software &amp; sensors. Taser develops and sells CEDs used for protecting users and virtual reality training. Software and sensors manufacture fully integrated hardware and cloud-based software solutions such as body cameras, automated license plate reading, and digital evidence management systems. Axon delivers its products worldwide and derives the majority of its revenue from the software &amp; sensors segment and geographically from the United States.</p>
<h3>Axon Enterprise's Current Market Status</h3>
<ul>
<li>With a trading volume of 448,737, the price of AXON is down by -0.08%, reaching $525.03.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 66 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Axon Enterprise</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $680.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $600.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on Axon Enterprise, maintaining a target price of $726.<br />
&#x2A; Reflecting concerns, an analyst from Craig-Hallum lowers its rating to Hold with a new price target of $625.<br />
&#x2A; Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for Axon Enterprise, targeting a price of $725.<br />
&#x2A; An analyst from Citizens Capital Markets has revised its rating downward to Market Outperform, adjusting the price target to $725. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Axon Enterprise, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


AXON

Looking At Axon Enterprise's Recent Unusual Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Oklo</strong>.</p>
<p>Looking at options history for Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) we detected 35 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 48% of the investors opened trades with bullish expectations and 42% with bearish.</p>
<p>From the overall spotted trades, 20 are puts, for a total amount of $852,722 and 15, calls, for a total amount of $675,968.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $47.0 for Oklo over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Oklo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Oklo's substantial trades, within a strike price spectrum from $20.0 to $47.0 over the preceding 30 days.</p>
<h3>Oklo Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772836_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OKLO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.9</td>
<td>$5.65</td>
<td>$5.73</td>
<td>$22.50</td>
<td>$257.8K</td>
<td>979</td>
<td>1.0K</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/07/25</td>
<td>$2.26</td>
<td>$2.14</td>
<td>$2.14</td>
<td>$36.00</td>
<td>$85.6K</td>
<td>180</td>
<td>892</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.3</td>
<td>$5.9</td>
<td>$6.3</td>
<td>$30.00</td>
<td>$62.3K</td>
<td>3.1K</td>
<td>118</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$11.9</td>
<td>$11.2</td>
<td>$11.8</td>
<td>$34.00</td>
<td>$59.0K</td>
<td>15</td>
<td>62</td>
</tr>
<tr>
<td>OKLO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$12.15</td>
<td>$11.5</td>
<td>$11.72</td>
<td>$33.00</td>
<td>$58.6K</td>
<td>29</td>
<td>50</td>
</tr>
</tbody>
</table>
</p>
<h3>About Oklo</h3>
<p>Oklo Inc is developing advanced fission power plants to provide clean, reliable, and affordable energy at scale. It is pursuing two complementary tracks to address this demand: providing reliable, commercial-scale energy to customers; and selling used nuclear fuel recycling services to the U.S. market. The Company plans to commercialize its liquid metal fast reactor technology with the Aurora powerhouse product line. The first commercial Aurora powerhouse is designed to produce up to 15 megawatts of electricity (MWe) on both recycled nuclear fuel and fresh fuel.</p>
<p>In light of the recent options history for Oklo, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Oklo</h3>
<ul>
<li>With a volume of 11,182,131, the price of OKLO is up 2.07% at $33.06. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>What The Experts Say On Oklo</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $58.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on Oklo, maintaining a target price of $58. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Oklo with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


OKLO

Oklo's Options: A Look at What the Big Money is Thinking

<p>In the latest quarter, 8 analysts provided ratings for Vertex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERX#NASDAQ">VERX</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.75, a high estimate of $62.00, and a low estimate of $31.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 10.11%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772832_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The perception of Vertex by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Samad Samana</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$31.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Announces</td>
<td>Buy</td>
<td>$62.00</td>
<td>-</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Steven Enders</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$61.00</td>
<td>$61.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Vertex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Vertex compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Capture valuable insights into Vertex's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VERX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vertex analyst ratings.</strong></a></p>
<h2>Delving into Vertex's Background</h2>
<p>Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. Vertex provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting among others. The company derives revenue from software subscriptions.</p>
<h3>Financial Insights: Vertex</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Vertex's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>17.52%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Vertex's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>4.24%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Vertex's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>2.93%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.65%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.36</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VERX

What Analysts Are Saying About Vertex Stock

<p>Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $192.56, a high estimate of $200.00, and a low estimate of $180.00. This current average reflects an increase of 13.44% from the previous average price target of $169.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772825_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Natera is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$195.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$188.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$200.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Kyle Mikson</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Julia Qin</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Natera. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Natera compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Natera's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Natera's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NTRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Natera analyst ratings.</strong></a></p>
<h2>Delving into Natera's Background</h2>
<p>Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.</p>
<h3>Natera: A Financial Overview</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Natera showcased positive performance, achieving a revenue growth rate of <strong>63.9%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Natera's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-7.18%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Natera's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-3.68%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Natera's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.03%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Natera's debt-to-equity ratio is below the industry average at <strong>0.54</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


NTRA

Deep Dive Into Natera Stock: Analyst Perspectives (9 Ratings)

<p>In the latest quarter, 13 analysts provided ratings for Equitable Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQH#NYSE">EQH</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $61.31, a high estimate of $72.00, and a low estimate of $53.00. Witnessing a positive shift, the current average has risen by 9.0% from the previous average price target of $56.25.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1740772814_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Equitable Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$66.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Nigel Dally</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jack Matten</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Cave Montazeri</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$53.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$61.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Ryan Krueger</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Equitable Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Equitable Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Equitable Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Equitable Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EQH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Equitable Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Equitable Holdings</h2>
<p>Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.</p>
<h3>Breaking Down Equitable Holdings's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Equitable Holdings showcased positive performance, achieving a revenue growth rate of <strong>66.87%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Equitable Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>24.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Equitable Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>100.58%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Equitable Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>0.29%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>76.27</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

NetEase Stock News

News

Latest NetEase Stock News | OTC:NETTF | Benzinga

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga